一个与DNA损伤相关的新型基因指数用于预测胃癌的预后
Haipeng Xiao1, Qianjin He2, Yang Hu3
1Department of General Surgery, Huanggang Central Hospital of Yangtze University, Huanggang, China.
3 Biotech
|January 7, 2025
概括
这项研究确定了胃癌中两种DNA损伤亚型,并开发了基于12个基因的预后模型. 该模型预测患者的存活率和免疫治疗的反应,帮助个性化治疗策略.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 生物信息学是一种生物信息学.
背景情况:
- 胃癌是癌症死亡的主要原因,具有显著的异质性.
- 精确的预后模型对于改善胃癌治疗策略至关重要.
- DNA损伤在瘤的进展和发育中起着关键作用.
研究的目的:
- 根据DNA损伤相关的基因,将胃癌患者分为不同的亚型.
- 构建和验证一种基于机器学习的胃癌预后模型.
- 调查基因表达模式,药物敏感性和免疫治疗反应与DNA损伤亚型有关的研究.
主要方法:
- 来自TCGA队列的DNA损伤相关基因的共识聚类分析.
- 机器学习算法和考克斯回归用于预后模型构建.
- 使用GSE胃癌队列和基因映射分析进行验证.
主要成果:
- 在胃癌患者中确定了两种不同的DNA损伤亚型.
- 开发了一个使用12个差异表达基因的预后模型,计算患者的风险得分.
- 较高的风险得分与降低药物敏感性,较低的整体存活率和潜在的较差的免疫治疗反应相关.
结论:
- 这12个基因的预后特征有效预测胃癌的预后和整体存活率.
- 鉴定的风险评分可以指导治疗决策,包括免疫治疗.
- 研究结果支持向DNA损伤和免疫微环境,以提高胃癌治疗结果.
相关概念视频
DNA Damage can Stall the Cell Cycle
9.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.0K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K


